Cargando…

Atheroprotective Vaccination with MHC-II Restricted Peptides from ApoB-100

Background: Subsets of CD4(+) T-cells have been proposed to serve differential roles in the development of atherosclerosis. Some T-cell types are atherogenic (T-helper type 1), while others are thought to be protective (regulatory T-cells). Lineage commitment toward one type of helper T-cell versus...

Descripción completa

Detalles Bibliográficos
Autores principales: Tse, Kevin, Gonen, Ayelet, Sidney, John, Ouyang, Hui, Witztum, Joseph L., Sette, Alessandro, Tse, Harley, Ley, Klaus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3873602/
https://www.ncbi.nlm.nih.gov/pubmed/24416033
http://dx.doi.org/10.3389/fimmu.2013.00493
_version_ 1782297132258033664
author Tse, Kevin
Gonen, Ayelet
Sidney, John
Ouyang, Hui
Witztum, Joseph L.
Sette, Alessandro
Tse, Harley
Ley, Klaus
author_facet Tse, Kevin
Gonen, Ayelet
Sidney, John
Ouyang, Hui
Witztum, Joseph L.
Sette, Alessandro
Tse, Harley
Ley, Klaus
author_sort Tse, Kevin
collection PubMed
description Background: Subsets of CD4(+) T-cells have been proposed to serve differential roles in the development of atherosclerosis. Some T-cell types are atherogenic (T-helper type 1), while others are thought to be protective (regulatory T-cells). Lineage commitment toward one type of helper T-cell versus another is strongly influenced by the inflammatory context in which antigens are recognized. Immunization of atherosclerosis-prone mice with low-density lipoprotein (LDL) or its oxidized derivative (ox-LDL) is known to be atheroprotective. However, the antigen specificity of the T-cells induced by vaccination and the mechanism of protection are not known. Methods: Identification of two peptide fragments (ApoB(3501–3516) and ApoB(978–993)) from murine ApoB-100 was facilitated using I-Ab prediction models, and their binding to I-Ab determined. Utilizing a vaccination scheme based on complete and incomplete Freund’s adjuvant (CFA and IFA) [1 × CFA + 4 × IFA], we immunized Apoe(−/−)mice with ApoB(3501–3516) or ApoB(978–993) emulsified in CFA once and subsequently boosted in IFA four times over 15 weeks. Spleens, lymph nodes, and aortas were harvested and evaluated by flow cytometry and real time RT-PCR. Total atherosclerotic plaque burden was determined by aortic pinning and by aortic root histology. Results: Mice immunized with ApoB(3501–3516) or ApoB(978–993) demonstrated 40% reduction in overall plaque burden when compared to adjuvant-only control mice. Aortic root frozen sections from ApoB(3501–3516) immunized mice showed a >60% reduction in aortic sinus plaque development. Aortas from both ApoB(3501–3516) and ApoB(978–993) immunized mice contained significantly more mRNA for IL-10. Both antigen-specific IgG1 and IgG2c titers were elevated in ApoB(3501–3516) or ApoB(978–993) immunized mice, suggesting helper T-cell immune activity after immunization. Conclusion: Our data show that MHC Class II restricted ApoB-100 peptides can be atheroprotective, potentially through a mechanism involving elevated IL-10.
format Online
Article
Text
id pubmed-3873602
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-38736022014-01-11 Atheroprotective Vaccination with MHC-II Restricted Peptides from ApoB-100 Tse, Kevin Gonen, Ayelet Sidney, John Ouyang, Hui Witztum, Joseph L. Sette, Alessandro Tse, Harley Ley, Klaus Front Immunol Immunology Background: Subsets of CD4(+) T-cells have been proposed to serve differential roles in the development of atherosclerosis. Some T-cell types are atherogenic (T-helper type 1), while others are thought to be protective (regulatory T-cells). Lineage commitment toward one type of helper T-cell versus another is strongly influenced by the inflammatory context in which antigens are recognized. Immunization of atherosclerosis-prone mice with low-density lipoprotein (LDL) or its oxidized derivative (ox-LDL) is known to be atheroprotective. However, the antigen specificity of the T-cells induced by vaccination and the mechanism of protection are not known. Methods: Identification of two peptide fragments (ApoB(3501–3516) and ApoB(978–993)) from murine ApoB-100 was facilitated using I-Ab prediction models, and their binding to I-Ab determined. Utilizing a vaccination scheme based on complete and incomplete Freund’s adjuvant (CFA and IFA) [1 × CFA + 4 × IFA], we immunized Apoe(−/−)mice with ApoB(3501–3516) or ApoB(978–993) emulsified in CFA once and subsequently boosted in IFA four times over 15 weeks. Spleens, lymph nodes, and aortas were harvested and evaluated by flow cytometry and real time RT-PCR. Total atherosclerotic plaque burden was determined by aortic pinning and by aortic root histology. Results: Mice immunized with ApoB(3501–3516) or ApoB(978–993) demonstrated 40% reduction in overall plaque burden when compared to adjuvant-only control mice. Aortic root frozen sections from ApoB(3501–3516) immunized mice showed a >60% reduction in aortic sinus plaque development. Aortas from both ApoB(3501–3516) and ApoB(978–993) immunized mice contained significantly more mRNA for IL-10. Both antigen-specific IgG1 and IgG2c titers were elevated in ApoB(3501–3516) or ApoB(978–993) immunized mice, suggesting helper T-cell immune activity after immunization. Conclusion: Our data show that MHC Class II restricted ApoB-100 peptides can be atheroprotective, potentially through a mechanism involving elevated IL-10. Frontiers Media S.A. 2013-12-27 /pmc/articles/PMC3873602/ /pubmed/24416033 http://dx.doi.org/10.3389/fimmu.2013.00493 Text en Copyright © 2013 Tse, Gonen, Sidney, Ouyang, Witztum, Sette, Tse and Ley. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Tse, Kevin
Gonen, Ayelet
Sidney, John
Ouyang, Hui
Witztum, Joseph L.
Sette, Alessandro
Tse, Harley
Ley, Klaus
Atheroprotective Vaccination with MHC-II Restricted Peptides from ApoB-100
title Atheroprotective Vaccination with MHC-II Restricted Peptides from ApoB-100
title_full Atheroprotective Vaccination with MHC-II Restricted Peptides from ApoB-100
title_fullStr Atheroprotective Vaccination with MHC-II Restricted Peptides from ApoB-100
title_full_unstemmed Atheroprotective Vaccination with MHC-II Restricted Peptides from ApoB-100
title_short Atheroprotective Vaccination with MHC-II Restricted Peptides from ApoB-100
title_sort atheroprotective vaccination with mhc-ii restricted peptides from apob-100
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3873602/
https://www.ncbi.nlm.nih.gov/pubmed/24416033
http://dx.doi.org/10.3389/fimmu.2013.00493
work_keys_str_mv AT tsekevin atheroprotectivevaccinationwithmhciirestrictedpeptidesfromapob100
AT gonenayelet atheroprotectivevaccinationwithmhciirestrictedpeptidesfromapob100
AT sidneyjohn atheroprotectivevaccinationwithmhciirestrictedpeptidesfromapob100
AT ouyanghui atheroprotectivevaccinationwithmhciirestrictedpeptidesfromapob100
AT witztumjosephl atheroprotectivevaccinationwithmhciirestrictedpeptidesfromapob100
AT settealessandro atheroprotectivevaccinationwithmhciirestrictedpeptidesfromapob100
AT tseharley atheroprotectivevaccinationwithmhciirestrictedpeptidesfromapob100
AT leyklaus atheroprotectivevaccinationwithmhciirestrictedpeptidesfromapob100